TCGA-DK-A1AC-01A-11R-A13Y-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 130.781866
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.570
- E2F_TARGETS+0.530
- MYC_TARGETS_V2+0.500
- UNFOLDED_PROTEIN_RESPONSE+0.500
- G2M_CHECKPOINT+0.450
- PROTEIN_SECRETION+0.380
- OXIDATIVE_PHOSPHORYLATION+0.360
- MTORC1_SIGNALING+0.350
- TNFA_SIGNALING_VIA_NFKB+0.310
- ALLOGRAFT_REJECTION+0.260
Top 10 suppressed
- APICAL_SURFACE-0.390
- ESTROGEN_RESPONSE_LATE-0.360
- INTERFERON_ALPHA_RESPONSE-0.360
- MYOGENESIS-0.340
- COAGULATION-0.310
- KRAS_SIGNALING_DN-0.310
- APICAL_JUNCTION-0.260
- ESTROGEN_RESPONSE_EARLY-0.260
- NOTCH_SIGNALING-0.250
- P53_PATHWAY-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | X11368e6c.aeb6.4de4.8e74.436b1cd1846c | — | cohortA1 | 0.821 |
| 2 | SRR8518311 | — | E | 0.813 |
| 3 | c192c50f-0236-4d28-9343-ce9d9c3ac291 | — | — | 0.812 |
| 4 | MDT-AP-3283 | Med | Medulloblastoma | 0.795 |
| 5 | d9eacc36-0ae3-41bd-aef6-503f91cb25aa | — | — | 0.790 |
| 6 | MDT-AP-0541 | Med | Medulloblastoma | 0.787 |
| 7 | SRR11296852 | — | — | 0.785 |
| 8 | SRR8518152 | — | E | 0.785 |
| 9 | 8027196b-a80b-4759-872d-b72c98905451 | — | — | 0.782 |
| 10 | TCGA-05-4415-01A-22R-1858-07 | — | cohortA4 | 0.779 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.570 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.500 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.260 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.150 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |